Recent advances in understanding T2 inflammation have broadened the diseases in which
T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody …

Recent advances in our understanding of T2 inflammation have revealed more diseases in
which T2 inflammation is involved. Dupilumab is a recently developed monoclonal antibody …

Moderate and severe forms of allergic diseases such as atopic dermatitis and asthma are a
challenge for clinicians. In these conditions, which severely affect the quality of life of the …

Dupilumab (Dupixent®) is a fully human monoclonal antibody directed against the
interleukin (IL)-4 receptor α (IL-4Rα) subunit. Dupilumab inhibits the signalling of the type 2 …

Atopic dermatitis (eczema) is a common chronic disease that is described as severe itching
associated with recurrent eczematous lesions. In 2017 the US Food and Drug Administration …

Atopic dermatitis (AD) is the most common chronic inflammatory disease affecting 2-10% of
adults and up to 15-30% of children. Despite a rising prevalence, effective and safe …

Atopic dermatitis (AD) is a chronic inflammatory condition that affects 5–10% of adults and 9–
18% of children and its pathology is rooted in the Th-2-mediated immune response …

Background Dupilumab is a receptor antagonist binding to the alpha subunit of the
interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL …

Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. The
prevalence of AD is increasing and is currently estimated at 10–20% in adults worldwide. In …

Introduction: Atopic dermatitis (AD) is a recurrent, pruritic inflammatory skin disease with
complex immunopathogenesis characterized by a dominant TH2 response. Dupilumab is an …